Skip to main content
Clinical Trials/ISRCTN18410689
ISRCTN18410689
Completed
Phase 4

A double blind-cross-over, parallel, randomized, multicenter study to evaluate the safety and efficacy of LTS035 (Lactosectan) vs placebo in adult subjects with intolerance to certain foods, primarily lactose intolerant

ovintethical Pharma SA0 sites60 target enrollmentDecember 16, 2021

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
actose intolerance
Sponsor
ovintethical Pharma SA
Enrollment
60
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36076786/ (added 06/01/2023)

Registry
who.int
Start Date
December 16, 2021
End Date
January 12, 2018
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ovintethical Pharma SA

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 to 64 years with a current or recently reported history of dairy intolerance of at least 1\-month duration
  • 2\. Caucasian race
  • 3\. Willing to sign the informed consent form

Exclusion Criteria

  • 1\. Pregnant or breastfeeding women
  • 2\. Unwilling to sign the informed consent form
  • 3\. Allergy to one of the product ingredients
  • 4\. Cannot to come to the study visits
  • 5\. Patients with celiac disease
  • 6\. Patients with gastroenteritis
  • 7\. Patients with Crohn’s disease
  • 8\. Using lactase enzyme tablets or drops
  • 9\. Used antibiotics in the last 4 weeks
  • 10\. Used laxatives in the last 2 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials